A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jie Wang, M.D.
Cancer hospital, Chinese academy of medical sciences and Peking union medical college
Principal Investigator - Qingming Wang
Henan Cancer Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
62 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
- Anhui Provincial Cancer Hospital
Hefei, Anhui, China
- Anhui Provincial Hospital
Hefei, Anhui, China
- the First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, China
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
- Beijing Chest Hospital
Beijing, Beijing Municipality, China
- Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China
- the Fifth Medical Center of the Chinese People'S Liberation Army General Hospital
Beijing, Beijing Municipality, China
- Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
- Fujian Cancer Hospital
Fuzhou, Fujian, China
- Zhangzhou Municipal Hospital of Fujian Province
Zhangzhou, Fujian, China
- Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
- Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, China
- Nanfang Hospital
Guangzhou, Guangdong, China
- the First Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
- Cancer Hospital Chinses Academy of Medical Sciences， Shenzhen Center
Shenzhen, Guangdong, China
- Hainan Cancer Hospital
Haikou, Hainan, China
- Affiliated Hospital of Hebei University
Baoding, Hebei, China
- the Second People'S Hospital of Hengshui
Hengshui, Hebei, China
- the Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
- the Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
- Tangshang People'S Hospital
Tangshan, Hebei, China
- Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
- Jiamusi Tuberculosis Prevention and Control Hospital (jiamusi Cancer Hospital)
Jiamusi, Heilongjiang, China
- the First Hospital of Qiqihar
Qiqihar, Heilongjiang, China
- the First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
- Nanyang Central Hospital
Nanyang, Henan, China
- the First Affiliated Hospital of Xinxiang Medical College
Xinxiang, Henan, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
- Hubei Cancer Hospital
Wuhan, Hubei, China
- Renmin Hospital of Wuhan University
Wuhan, Hubei, China
- Hunan Cancer Hospital
Changsha, Hunan, China
- the Second Xiangya Hospital, Central South University
Changsha, Hunan, China
- Xiangya Hospital of Central South University
Changsha, Hunan, China
- the First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
- the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
- First Affiliated Hospital of Gannan Medical College
Ganzhou, Jiangxi, China
- First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
- the First Hospital of Jilin Universit
Changchun, Jilin, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Nov 2023
- Primary completion
- 5 Aug 2025
- Completion
- 28 Nov 2026
- Last update posted
- 14 Aug 2023
- Registered enrollment
- 642
- Registry id
- NCT05990127
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.